leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2
Search Results
NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Presented by: Deborah M. Stephens
Emerging Therapies in the Treatment of Bladder Cancer
Presented by: Arlene O. Siefker-Radtke
personally am using growth factor support in all of my patients in [the setting of] sacituzumab govitecan because of neutropenia and neutropenic fever.” Combining Targeted Therapy With Immunotherapy “We are seeing a lot of excitement for [targeted
New Agents in Metastatic Prostate Cancer
Atish D. Choudhury and Philip W. Kantoff
was accompanied by increased toxicity compared with mitoxantrone, with higher rates of grade 3 or greater neutropenia (82% vs. 58%), neutropenic fever (8% vs. 1%), and diarrhea (6% vs. <1%), along with greater requirements for dose reductions (12% vs
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman
response was 5 months (range, 1–20+ months), with responses occurring in all sites of disease, including skin, bone marrow, and lymph nodes. Acute infusion-related adverse effects such as fever, chills, and nausea were mild to moderate in severity and were
Diagnostic Strategies for Invasive Fungal Infections in Patients With Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients
Maxim Norkin and John R. Wingard
disseminated infection less commonly seen. Candida infections of the mucosa occur early and throughout the course of neutropenia and/or immunosuppressive therapy. Candida fungemia is rarely the cause of first neutropenic fever, but may be a cause of
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group
Gary H. Lyman and Marek S. Poniewierski
) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients . Support Care Cancer 2013 ; 21 : 1487 – 1495 . 43. Talcott JA Siegel RD Finberg R . Risk assessment in cancer patients with fever and
Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
defined using one of the following methods: (1) neutropenia (ICD-9 code 288.0) and fever (ICD-9 code 780.6) within 7 days of hospitalization; (2) absolute neutrophil count (ANC) <1,000/mcL and fever (ICD-9 code 780.6) within 7 days of hospitalization; (3
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass
expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN website ( NCCN.org ). Initial Presentation Patients with DLBCL and BL may present with fever, chills, night sweats, unexplained
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar
GCSFs might be considered in patients with severe neutropenic fever after chemotherapy. HBV Reactivation: HBV reactivation leading to fulminant hepatitis, hepatic failure, and death have been reported in patients receiving chemotherapy and
Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+?
Jeffrey A. Gilreath, David D. Stenehjem, and George M. Rodgers
be given in 1 to 4 injections for children with iron-deficiency anemia. This method was appealing to clinicians because the reported incidence of reactions was on the order of only 1% and included symptoms such as fever, arthralgia, and